On October 17, 2019 Biocure Technology Inc. (CSE: CURE OTCQB: BICTF) (the "Company" or "Biocure") reported that Biocure Pharm Corp.("BPK"), a subsidiary of the Company has appointed CLIPS (Clinical Professional Services) as the CRO (Contract Research Organization) to proceed with a Clinical Trial for CAR-T products in Korea (Press release, Biocure Technology, OCT 17, 2019, View Source [SID1234628815]). After reviewing multiple competent CRO’s in Korea and multiple meetings with them, BPK has selected CLIPS who has outstanding experience as well as expertise in gene therapies and cell therapies. In addition, their knowledge of the clinical trials convinced BPK it could achieve a successful clinical trial for CAR-T products within the given timeline.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Sang Mok Lee, a CEO and President of Biocure as well as BPK states, "I am pleased to appoint CLIPS as our CRO to proceed to a clinical trial for CAR-T products in Korea, where our Company targets the first commercialization of our CAR-T products. Biocure has successfully completed there pre-clinical trial in Korea last October 2018 and now is fully geared to speed up the process of clinical trial in Korea through this CRO appointment. We should be able to start a clinical trial in Korea no later than January 2020 and in Germany within 2Q, 2020. Biocure will continue to make every effort to commercialize CAR-T products as soon as possible to meet the expectations of our shareholders."